APA (7th ed.) Citation

G, G., V, S., AM, Z., RS, K., V, P., S, R., . . . U, P. (2025). Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Advances in therapy, 42(7), 3576. https://doi.org/10.1007/s12325-025-03208-5

Chicago Style (17th ed.) Citation

G, Garcia-Manero, et al. "Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial." Advances in Therapy 42, no. 7 (2025): 3576. https://doi.org/10.1007/s12325-025-03208-5.

MLA (9th ed.) Citation

G, Garcia-Manero, et al. "Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial." Advances in Therapy, vol. 42, no. 7, 2025, p. 3576, https://doi.org/10.1007/s12325-025-03208-5.